NCT06115473

Brief Summary

Endotracheal intubation is a lifesaving procedure that is performed in various settings within the hospital or even in the pre-hospital field. However, it can result in serious hemodynamic complications, such as post-intubation hypotension (PIH) and cardiac arrest. Push-dose pressor (PDP) is common practice for rapid hemodynamic correction in post-intubation hypotension. In this study the investigators will use intravenous Epinephrine bolus for prevention of post intubation collapse in septic patients predicted by shock index in intensive care unit.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2023

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 30, 2023

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 3, 2023

Completed
28 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2024

Completed
Last Updated

November 8, 2023

Status Verified

October 1, 2023

Enrollment Period

4 months

First QC Date

October 30, 2023

Last Update Submit

November 6, 2023

Conditions

Outcome Measures

Primary Outcomes (2)

  • incidence of cardiac arrest during intubation

    cardiac arrest

    during and till 30 minutes after intubation

  • sever hypotension

    decrease \> 20% of baseline mean arterial blood pressure

    during and till 30 minutes after intubation

Secondary Outcomes (5)

  • incidence of arrythmias

    during and till 30 minutes after intubation

  • bradycardia

    during and till 30 minutes after intubation

  • increased lactate

    lactate will be measured 1 hour after intubation

  • need for or increase dose of postintubation vasopressor

    during and till 30 minutes after intubation

  • decreased oxygen saturation

    during and till 30 minutes after intubation

Study Arms (2)

E group for epinephrine

ACTIVE COMPARATOR

In Group (E) patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.

Drug: epinephrine

Group (F)

PLACEBO COMPARATOR

In Group (F) patients will receive IV bolus isotonic fluid 500 ml as it is yet the standard method used before intubation

Drug: isotonic fluid

Interventions

patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.

E group for epinephrine

patients will receive IV bolus isotonic fluid 500 ml

Group (F)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) \> 0.9.

You may not qualify if:

  • patient's family refusal, age \<18, pregnant, Patients with tachyarrhythmias, traumatic patients, patient with shock index \<0.9, ischemic heart patients, any comorbidities contraindicated to take epinephrine and allergic to epinephrine will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ain Shams University Hospitals at Intensive care units department

Cairo, 1181, Egypt

RECRUITING

MeSH Terms

Conditions

Shock

Interventions

Epinephrine

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: : septic patients of either sex above 18 years of age, will need emergent intubation during ICU admission, shock index (SI) \> 0.9.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 30, 2023

First Posted

November 3, 2023

Study Start

August 1, 2023

Primary Completion

December 1, 2023

Study Completion

January 1, 2024

Last Updated

November 8, 2023

Record last verified: 2023-10

Locations